Trial · NCT03525002
Dopamine Action on Metabolism in Relation to Genotype
NCT03525002, Phase 2, Completed, University Hospital Tuebingen
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Dopamine Action on Metabolism in Relation to Genotype. Trials, record NCT03525002. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03525002
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dopamine Action on Metabolism in Relation to Genotype
- NCT number
- NCT03525002
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 120 participants, actual
- Lead sponsor
- University Hospital Tuebingen
- Conditions
- Obesity
- Interventions
- Bromocriptine, Placebo
- First posted
- 2018-05-15
- Last updated
- 2025-11-24
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Interaction between FTO genotype and treatment on change in body weight. | 18 weeks | Interaction between FTO (single nucleotide peptide) SNP rs8050136 genotype and treatment (bromocriptine or placebo) on change in body weight. |
| Secondary | Effect of bromocriptine vs. placebo on body weight | 18 weeks | |
| Secondary | Effect of bromocriptine vs. placebo on dietary intake | 18 weeks | Dietary intake will be monitored by food diaries |
| Secondary | Effect of bromocriptine vs. placebo on processing of food cues in the brain | 18 weeks | Processing of food cues in the brain will be assessed by functional magnetic resonance imaging before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on body fat distribution | 18 weeks | Body fat distribution will be assessed by magnetic resonance imaging and magnetic resonance spectroscopy before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on whole body insulin sensitivity | 18 weeks | Whole body insulin sensitivity will be quantified from 5 point 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on insulin secretion | 18 weeks | Insulin secretion will be quantified from 5 point 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on glucose tolerance | 18 weeks | Glucose tolerance will be assessed by 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on brain insulin sensitivity | 18 weeks | Brain insulin sensitivity will be assessed by functional magnetic resonance imaging combined with intranasal insulin administration before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on resting energy expenditure | 18 weeks | Resting energy expenditure will be assessed by indirect calorimetry before and after treatment with bromocriptine or placebo |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03525002
GET https://conductscience.org/api/trials/v1/NCT03525002/registered